The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates
Open accessAbstract
Background: Adeno-associated vectors (rAAV) have been used to attain long-term liver gene expression. In humans, the cellular immune response poses a serious obstacle for transgene persistence while neutralizing humoral immunity curtails re-administration. Porphobilinogen deaminase (PBGD) haploinsufficiency (acute intermittent porphyria) benefits from liver gene transfer in mouse models and clinical trials are about to begin. In this work, we sought to study in non-human primates the feasibility of repeated gene-transfer with intravenous administration of rAAV5 vectors under the effects of an intensive immunosuppressive regimen and to analyze its ability to circumvent T-cell immunity and thereby prolong transgene expression. Methods: Three female Macaca fascicularis were intravenously injected with 1x10 13 genome copies/kg of rAAV5 encoding the human PBGD. Mycophenolate mofetil (MMF), anti-thymocyte immunoglobulin, methylprednisolone, tacrolimus and rituximab were given in combination during 12 weeks to block T- and B-cell mediated adaptive immune responses in two macaques. Immunodeficient and immunocompetent mice were intravenously injected with 5x10 12 genome copies/kg of rAAV5-encoding luciferase protein. Forty days later MMF, tacrolimus and rituximab were daily administrated to ascertain whether the immunosuppressants or their metabolites could interfere with transgene expression. Results: Macaques given a rAAV5 vector encoding human PBGD developed cellular and humoral immunity against viral capsids but not towards the transgene. Anti-AAV humoral responses were attenuated during 12 weeks but intensely rebounded following cessation of the immunosuppressants. Accordingly, subsequent gene transfer with a rAAV5 vector encoding green fluorescent protein was impossible. One macaque showed enhanced PBGD expression 25 weeks after rAAV5-pbgd administration but overexpression had not been detected while the animal was under immunosuppression. As a potential explanation, MMF decreases transgene expression in mouse livers that had been successfully transduced by a rAAV5 several weeks before MMF onset. Such a silencing effect was independent of AAV complementary strand synthesis and requires an adaptive immune system. Conclusions: These results indicate that our transient and intensive pharmacological immunosuppression fails to improve AAV5-based liver gene transfer in non-human primates. The reasons include an incomplete restraint of humoral immune responses to viral capsids that interfere with repeated gene transfer in addition to an intriguing MMF-dependent drug-mediated interference with liver transgene expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A 5-drug immunosuppression regimen, including anti-thymocyte globulin (ATG), tacrolimus, rituximab, MMF, and methylprednisolone, inhibited T cell response after IV AAV5 delivery in NHPs (79).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [79]
In the citing paper
“Pre-clinical studies have applied immunosuppression as an alternative to control anti-capsid cellular immune response (42–44).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [44]
In the citing paper
“Interestingly, NAb f o r m a t i o n occurred upon t h e r e m o v a l of immunosuppression.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [79]
In the citing paper
“This 5-drug regimen with rAAV5-PBGD 1×1013vg/kg infusion resulted in reduced T-cell response in NHP, but did not prevent NAb emergence following regimen removal.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 2×
“The finding that the cytotoxic T lymphocyte response eliminated gene expression in transduced cells was not observed in the clinical trial with rAAV8 trial where a course of glucocorticoid therapy was given [16].”
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 3×
“Secondly, prior infection of the patients with natural or recombinant AAVs leads to formation of memory CD8+ T cells which readily undergo activation upon re-exposure to the AAV capsids [8,9].”
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457 · cited 1×
“The rAAV5 vectors were generated in Sf9 insect cells [17].”
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 2×
“Several studies have suggested that rate of uncoating of vector genomes is lower with rAAV2 than with serotypes rAAV5, rAAV6 and rAAV8 [18,23].”
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · cited 1×
“In previous work from other laboratories performed in rhesus macaques, in only one animal of the three treated daily with MMF and tacrolimus for 6 weeks did the levels of anti-AAV8 IgG antibodies increase after IS therapy was stopped [12].”
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Mechanism of Action of Mycophenolate Mofetil
Ransom, J. T. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00023 · Cited by 284 · cited 1×
“Importantly, MMF was administered four weeks after injection of our single stranded AAV5 vector in order to avoid its interference effect on second-strand DNA synthesis [19,20].”
Nathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272 · cited 1×
“It could be that the more rapid uncoating of rAAV8 than of rAAV2 capsid proteins from viral particles [22,23] allows the rAAV8 capsid proteins to be degraded by transduced cells before the immune system can seek and destroy them.”
Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · cited 1×
“In another study, daily treatment with MMF and sirolimus for 10 weeks reduced humoral response against AAV2 capsid in rhesus macaques [10].”
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238 · cited 3×
“Secondly, prior infection of the patients with natural or recombinant AAVs leads to formation of memory CD8+ T cells which readily undergo activation upon re-exposure to the AAV capsids [8,9].”
Cited by
Targeting long non-coding RNA to therapeutically upregulate gene expression
Wahlestedt, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4018 · Cited by 532
Goertsen, D., Flytzanis, N. C., Goeden, N., Chuapoco, M. R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00969-4 · Cited by 420
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Metadata
- Authors
- Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., Prieto, J., Melero, I., & Fontanellas, A.
- Affiliations
- Centro de Investigación Médica Aplicada (ES)
- Clinica Universidad de Navarra (ES)
- Corresponding author
- Melero, Ignacio
- ORCID
- Venue
- Journal of Translational Medicine
- Published
- 2012-06-15
- Volume
- 10
- Issue
- 1
- Pages
- 122-122
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC3412719
- OpenAlex
- W2146402993
- Cited by
- 69
- References
- 29
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 7 · 2016: 1 · 2015: 10 · 2014: 4 · 2013: 4
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundación Mutua Madrileña (RD06/0020)
- European Commission (261506, 201842)
- Fundación Científica Asociación Española Contra el Cáncer
- Universidad de Navarra
- Ministerio de Ciencia e Innovación (SAF2011-22831)
- Gobierno de Navarra
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Surgery › Xenotransplantation and immune response
- Keywords
- liver gene transfer, immunosuppression, porphobilinogen deaminase, acute intermittent porphyria, T cell immunity, humoral immunity, mycophenolate mofetil, tacrolimus, rituximab, non-human primates, macaque, immunocompetent mice
- MeSH terms
- Dependovirus, Animals, Antigens, Viral, Capsid, DNA, Viral, Female, Genetic Vectors, Humans, Immunity, Immunosuppression Therapy, Immunosuppressive Agents, Injections, Intravenous, Liver, Macaca fascicularis, Mice, Transgenic, Mycophenolic Acid, Serotyping, Treatment Failure, Gene Transfer Techniques, Transgenes, Mice, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. https://app.cochat.ai/papers/10.1186/1479-5876-10-122
- The paper
- Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., Prieto, J., Melero, I., & Fontanellas, A. (2012). Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-10-122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.